CClinicalTrials.gg
Status unknownNCT05560880Updated Oct 6, 2022

High Intensity Interval Gait Training in Multiple Sclerosis

An interventional study of High Intensity Interval Gait training and Moderate Intensity Interval gait training in Multiple Sclerosis, sponsored by Hunter College of City University of New York. Status unknown at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-10-06.

Sponsored by Hunter College of City University of New York · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Sep 2022), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Over 90% of persons with MS (pwMS) complain of difficulty with walking. High intensity interval gait training (HIIGT), where persons alternate brief periods of walking at high speeds with periods of rest has been found to improve walking in other neurologic diagnoses. However its impact on pwMS is not known. Most gait training in MS is done continuously at a slower pace. The purpose of this study is to compare the effects of HIIGT to traditional Moderate Intensity Continuous Gait Training (MICGT) in pwMS.

Read the detailed description

Purpose: To determine whether pwMS will have greater improvements in gait with HIIGT as compared to MICGT.

Primary Question: Does HIIGT results in greater improvements in gait parameters in pwMS than MICGT? Secondary question: Will HIIGT result in greater improvements in balance, lower extremity strength, lower extremity range of motion and HR when compared to MICGT in pwMS?

Hypothesis: HIIGT will result in greater improvements in gait parameters in pwMS than MICGT.

Justification: Previous research has shown that MICGT, moderate intensity interval training and high intensity non-gait interval training is effective in pwMS. HIIGT has been shown to be effective in persons with stroke but the effects of HIIGT on pwMS are not known.

Outcomes and dissemination of information: We will present our findings at national conferences and submit manuscripts of our findings to the appropriate peer reviewed journal.

02

Conditions studied

  • Multiple Sclerosis
03

In context

Multiple Sclerosis

3,460 studies on the registry are indexed under Multiple Sclerosis; 661 are open to participants now.

This study's planned enrollment of 30 is below the median of 50 across 2,342 interventional studies indexed under Multiple Sclerosis.

Browse Multiple Sclerosis studies →

Lead sponsor

Hunter College of City University of New York is the lead sponsor of 36 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Persons diagnosed with Multiple Sclerosis.
  • The ability to walk for 6 minutes continuously with or without assistive device.
  • The ability to read, understand and sign a consent form so that they are able to understand the study we are doing
  • Above the age of 18

Exclusion criteria

Exclusion Criteria:

  • Any cardiopulmonary, orthopedic, or non-MS neurologic disease as we are only examining the effects of MS and need to rule out the impact of other conditions
  • Report of a recent exacerbation. Rationale: the impact of the rationale can interfere with the impact of the independent variables
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    High Intensity Interval gait training

    subjects will receive 3x/week high intensity interval training for 20 minutes over a 4 week period

    Behavioral: High Intensity Interval Gait training

  • Active comparator
    Moderate intensity continuous gait training

    subjects will receive 3x/week moderate intensity continuous gait training for 20 minutes over a 4 week period

    Behavioral: Moderate Intensity Interval gait training

Interventions

  • BehavioralHigh Intensity Interval Gait training

    Subjects will walk as fast as they can for 30 seconds, followed by a 60 second seated recovery. They will be guarded by a physical therapist at all times.

  • BehavioralModerate Intensity Interval gait training

    subjects will walk for 20 minutes at theri best comfortable pace

06

What researchers measure

Primary outcomes

  1. Change in Six minute walk test time from before to after the intervention

    Subjects will walk for six minutes at their best comfortable pace. They will be guarded by physical therapist for the entire walk. Total distance, distance per minute, and heart rate will be measured.

    Time frame: The test will be administered to all subjects one week before and one week after the intervention.The test will be administered to all subjects one week before and one week after the intervention.

Secondary outcomes

  1. Change in Functional gait assessment score from before to after the intervention

    Used to assess balance during different walking conditions

    Time frame: Will be done in the week before and the week after the intervention.Will be done in the week before and the week after the intervention.

  2. Change in Hand held dynamometry values from before to after the intervention

    Use of the strain gauge to determine lower extremity muscle strength

    Time frame: Will be done the week before and the week after the intervention.

  3. Change in Multiple sclerosis impact scale 29 from before to afterthe intervention

    Quality of life measure where are the subject subjectively rates the impact of multiple sclerosis on their life

    Time frame: Performed in the week before and the week after the intervention.

07

Study locations

1 of 1 sites recruiting
  • Hunter College
    New York, New York 11238, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 6, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05560880
Lead sponsor
Hunter College of City University of New York
Responsible party
Herbert Karpatkin (Associate professor, Hunter College of City University of New York) — Principal investigator
First posted
Sep 30, 2022
Start date
Sep 1, 2022
Primary completion
Dec 31, 2023 (estimated)
Completion
Dec 31, 2023 (estimated)
Last update
Oct 6, 2022

Study contacts

Herb Karpatkin, DSc
Contact
hkarpatk@hunter.cuny.edu
212-396-7115

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion